Context Gonadotropin-releasing hormone agonists (GnRHas) are standard of care for
central precocious puberty (CPP). A 6-month subcutaneous injection has recently been …

This article presents the author's perspective on the diagnosis of central precocious puberty
(CPP) and its treatment with gonadotropin-releasing hormone (GnRH) analogues. Recent …

Managing precocious puberty (PP) has been a challenge due to lack of standardized
definition, gonadotrophins assay, gonadotrophin stimulation, timings for blood sampling …

Objective The present study aimed to assess the diagnostic utility of the Luteinizing hormone
(LH) levels and single 60-minute post gonadotropin-releasing hormone (GnRH) agonist …

Summary Context The G n RH test is the gold standard to confirm the diagnosis of central
precocious puberty (CPP); however, this compound is not always readily available …

Abstract Objective Depot GnRH agonists are commonly used in the treatment of central
precocious puberty (CPP). The triptorelin 11.25 mg 3-month depot, currently used in adult …

Background/Aims: There are few studies in the literature that have evaluated the etiological
factors in boys with central precocious puberty (CPP), and these studies are limited in terms …

Background It has been recommended that basal luteinising hormone (LH) levels be used
as the initial test to identify cases of central precocious puberty (CPP) in children. However …

Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central
precocious puberty (CPP) worldwide and have an enviable track record of safety and …

Background: A test involving 100 μg of intravenous gonadotropin-releasing hormone
(GnRH) is a gold standard for confirming the diagnosis of central precocious puberty (CPP) …